Ovarian Cancer – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Ovarian Cancer – Pipeline Review, H1 2020’, provides an overview of the Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer

– The report reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ovarian Cancer therapeutics and enlists all their major and minor projects

– The report assesses Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ovarian Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

4SC AG

Aadi Bioscience Inc

AB Science SA

AbbVie Inc

AbClon Inc

Abion Inc

ABL Bio Inc

ABM Therapeutics Inc

Acepodia Biotech Inc

Acrotech Biopharma LLC

Adaptimmune Therapeutics Plc

Adare Pharmaceuticals Inc

ADC Therapeutics SA

Adgero Biopharmaceuticals Holdings Inc

Adlai Nortye Biopharma Co Ltd

ADRx Inc

Advanced Cancer Therapeutics LLC

Advenchen Laboratories LLC

Adze Biotechnology Inc

Affimed GmbH

Affina Biotechnologies Inc

Agency for Science, Technology and Research

Agenus Inc

AIM ImmunoTech Inc

AiVita Biomedical Inc

Aldeyra Therapeutics Inc

Alfasigma SpA

Alkermes Plc

Allife Medical Science and Technology Co Ltd

Alligator Bioscience AB

Allist Shanghai Pharmaceutical Technology Co Ltd

Almac Discovery Ltd

Alteogen Inc

ALX Oncology Inc

Ambrx Inc

Amgen Inc

Amplia Therapeutics Ltd

Anew Oncology Inc

AnGes Inc

Angex Pharmaceutical Inc

Anixa Biosciences Inc

ANP Technologies Inc

AntiCancer Inc

Anwita Biosciences Inc

AP Biosciences Inc

Apexian Pharmaceuticals Inc

Apexigen Inc

Aphios Corp

Apollomics Inc

Apotex Inc

Aprea Therapeutics AB

Aprogen Inc

Aravive Inc

Arch Oncology Inc

Arcus Biosciences Inc

Argenx SE

Arrien Pharmaceuticals LLC

Asana BioSciences LLC

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Aslan Pharmaceuticals Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Athenex Inc

Atreca Inc

Atrin Pharmaceuticals LLC

Aurigene Discovery Technologies Ltd

Avicanna Inc

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BBS NanoTechnology Ltd

BeiGene Ltd

Beijing Fogangren Bio-Pharm Tech Co Ltd

Beijing Foreland Pharma Co Ltd

Beijing Neoantigen Biotechnology Co Ltd

Bicycle Therapeutics Plc

Bio-Path Holdings Inc

Bio-Thera Solutions Ltd

BioAtla LLC

BIOCND Inc

BioEclipse Therapeutics Inc

BioIntegrator Ltd

Biokine Therapeutics Ltd

BioMed Valley Discoveries Inc

BioMoti Ltd

BioNTech SE

BioVaxys LLC

bluebird bio Inc

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Byondis BV

Canget BioTekpharma LLC

Cardiff Oncology Inc

Carisma Therapeutics Inc

Carlina Technologies SAS

CaroGen Corp

Carrick Therapeutics Ltd

Carrick Therapeutics UK Ltd

Cartherics Pty Ltd

CAS-Lamvac Biotech Co Ltd

Cellatoz Therapeutics Inc

Celldex Therapeutics Inc

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cello Therapeutics Inc

Celprogen Inc

Celsion Corp

Celtec Inc

Celyad Oncology

Centurion BioPharma Corp

CerRx Inc

CG Oncology Inc

CHA Biotech Co Ltd

Checkmate Pharmaceuticals Inc

Chipscreen Biosciences Ltd

Chongqing Pharmaceutical Research Institute Co Ltd

Clarity Pharmaceuticals Pty Ltd

Claudin Technologies LLC

Clayton Biotechnologies Inc

Cloaked Therapeutics LLC

Clovis Oncology Inc

CMG Pharmaceutical Co Ltd

CNS Pharmaceuticals Inc

CohBar Inc

Coherent Biopharma

Commence Bio Inc

Compugen Ltd

Context Therapeutics LLC

Convert Pharmaceuticals SA

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

Cristal Therapeutics BV

Cue Biopharma Inc

CureLab Oncology Inc

Curis Inc

Cyclacel Pharmaceuticals Inc

Cynvec LLC

Cyteir Therapeutics Inc

Cytocom Inc

Cytodyn Inc

CZ BioMed Corp

DAE HWA Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

DC Prime BV

Deciphera Pharmaceuticals Inc

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Delta-Fly Pharma Inc

DevaCell Inc

Disulfican Ltd

Dongkook Pharmaceutical Co Ltd

Dophen Biomed Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Co

Elicio Therapeutics

Ellipses Pharma Ltd

Elthera AG

Elucida Oncology Inc

ENB Therapeutics LLC

EntreChem SL

EpicentRx Inc

Epigen Biosciences Inc

Epigene Therapeutics Inc

Epizyme Inc

Epsilogen Ltd

Epygen Biotech Pvt Ltd

Ervaxx Ltd

Esperance Pharmaceuticals Inc

Esperas Pharma Inc

Essential Biotechnology LLC

Eureka Therapeutics Inc

Evestra Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Falcon Therapeutics Inc

Faron Pharmaceuticals Oy

Fate Therapeutics Inc

For-Robin Inc

Fujifilm Holdings Corp

GAiA BioMedicine Inc

GamaMabs Pharma SA

Gene Techno Science Co Ltd

Genekey Biotech Chengdu Co Ltd

Genelux Corp

Genentech Inc

Geneos Therapeutics Inc

Genisphere LLC

Genmab AS

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

GLG Pharma SA

Glycomantra Inc

GlycoNex Inc

Glysantis Inc

Gmax Biopharm Ltd

GO Therapeutics Inc

GP Pharm SA

Gracell Biotechnology Ltd

Gradalis Inc

GT Biopharma Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Guangzhou Hanghua Bio Pharmaceutical Technology Co

Hangzhou Neoantigen Therapeutics Co Ltd

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Table of Contents

Table of Contents

Introduction

Ovarian Cancer - Overview

Ovarian Cancer - Therapeutics Development

Ovarian Cancer - Therapeutics Assessment

Ovarian Cancer - Companies Involved in Therapeutics Development

Ovarian Cancer - Drug Profiles

Ovarian Cancer - Dormant Projects

Ovarian Cancer - Discontinued Products

Ovarian Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Ovarian Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020

Ovarian Cancer – Pipeline by 4D Pharma Plc, H1 2020

Ovarian Cancer – Pipeline by 4SC AG, H1 2020

Ovarian Cancer – Pipeline by Aadi Bioscience Inc, H1 2020

Ovarian Cancer – Pipeline by AB Science SA, H1 2020

Ovarian Cancer – Pipeline by AbbVie Inc, H1 2020

Ovarian Cancer – Pipeline by AbClon Inc, H1 2020

Ovarian Cancer – Pipeline by Abion Inc, H1 2020

Ovarian Cancer – Pipeline by ABL Bio Inc, H1 2020

Ovarian Cancer – Pipeline by ABM Therapeutics Inc, H1 2020

Ovarian Cancer – Pipeline by Acepodia Biotech Inc, H1 2020

Ovarian Cancer – Pipeline by Acrotech Biopharma LLC, H1 2020

Ovarian Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2020

Ovarian Cancer – Pipeline by Adare Pharmaceuticals Inc, H1 2020

Ovarian Cancer – Pipeline by ADC Therapeutics SA, H1 2020

Ovarian Cancer – Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020

Ovarian Cancer – Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020

Ovarian Cancer – Pipeline by ADRx Inc, H1 2020

Ovarian Cancer – Pipeline by Advanced Cancer Therapeutics LLC, H1 2020

Ovarian Cancer – Pipeline by Advenchen Laboratories LLC, H1 2020

Ovarian Cancer – Pipeline by Adze Biotechnology Inc, H1 2020

Ovarian Cancer – Pipeline by Affimed GmbH, H1 2020

Ovarian Cancer – Pipeline by Affina Biotechnologies Inc, H1 2020

Ovarian Cancer – Pipeline by Agency for Science, Technology and Research, H1 2020

Ovarian Cancer – Pipeline by Agenus Inc, H1 2020

List of Figures

List of Figures

Number of Products under Development for Ovarian Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports